Clinical Trial Update: The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial [Phase 4]

View source ↗

Summary

A Phase 4 randomized, double-blind trial evaluated the safety and efficacy of XSLJZ in advanced hepatocellular carcinoma patients previously treated with multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• XSLJZ

Snippet

Sponsor: China Medical University Hospital | Conditions: Hepatocellular Carcinoma | Phase 4 | Status: COMPLETED